ASCO Annual Meeting | Conference

Practice-Changing Data Revealed for Premenopausal HR+ Breast Cancer

June 2nd 2014

A joint analysis of two phase III trials involving a total of 4690 premenopausal women with hormone-receptor–positive (HR+) breast cancer demonstrated that adjuvant use of the aromatase inhibitor (AI), exemestane, reduced relative risk of developing subsequent invasive cancer by 28% compared with tamoxifen when both agents were combined with ovarian function suppression (OFS).

T-VEC Combinations, Monotherapy Intriguing in Unresectable Melanoma

June 2nd 2014

The intratumoral injection talimogene laherparepvec demonstrated promise in combinations and utility as a monotherapy in certain subsets of patients with unresectable melanoma.

HPV-Targeting Immunotherapy Shows Early Promise in Cervical Cancer

June 2nd 2014

Two patients with metastatic cervical cancer achieved durable complete responses that have so far lasted from 15 to 22 months through an adoptive T-cell therapy (ACT) targeting the human papillomavirus (HPV) in a study that researchers say supports the concept that the experimental immunotherapy approach may be beneficial in a variety of tumor types.

New Study Findings Confirm Pembrolizumab's Durable Responses in Metastatic Melanoma

June 2nd 2014

The anti-PD 1 checkpoint inhibitor, pembrolizumab, continues to deliver impressive results in patients with advanced melanoma-producing long-lasting responses and improved overall survival, regardless of whether patients have been previously treated with ipilimumab.

Adjuvant Ipilimumab Reduces Risk of Recurrence in Stage III Melanoma

June 2nd 2014

The immunotherapy drug ipilimumab reduced the relative risk of cancer recurrence in the adjuvant setting by 25% compared to placebo for patients with high-risk, lymph-node positive melanoma.

Dr. Andtbacka Discusses OS With T-VEC in Melanoma

June 2nd 2014

Robert H. I. Andtbacka, MD, CM, from the Huntsman Cancer Institute, discusses OS findings from the phase III OPTiM study that explored T-VEC in patients with unresectable melanoma.

Dr. Fong Discusses Intratumoral Electroporation of Plasmid IL-12 in Melanoma

June 2nd 2014

Lawrence Fong, MD, from the University of California, San Francisco, discusses the systemic antitumor effect and clinical response in a phase II trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma.

Dr. Bendell Discusses Two Studies in BRAF-Mutated CRC

June 2nd 2014

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses two studies in BRAF-mutated colorectal cancer.

CO-1686 Continues to Show Promising Results in Treatment-Resistant NSCLC

June 1st 2014

The third-generation EGFR inhibitor CO-1686 continues to demonstrate promising activity in patients with non–small cell lung cancer (NSCLC) who developed resistance after prior treatment with an EGFR tyrosine kinase inhibitor (TKI).

Dr. Rizvi on Nivolumab Plus Erlotinib in Patients with EGFR MT NSCLC

June 1st 2014

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses the safety and response with plus erlotinib in patients with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC).

Survival Comparable With Bevacizumab, Cetuximab in mCRC

June 1st 2014

Frontline therapy with bevacizumab (Avastin) or cetuximab (Erbitux) combined with either FOLFOX or FOLFIRI yielded a comparable survival benefit of approximately 29 months in patients with KRAS wild-type metastatic colorectal cancer

Adding Chemo to ADT Confers Dramatic Survival Gains in Prostate Cancer

June 1st 2014

In what was described as "an almost unprecedented improvement in median survival," the addition of the chemotherapy drug docetaxel to standard hormone therapy prolonged life for men with newly diagnosed metastatic, hormone-sensitive prostate cancer by nearly 14 months.

Negative ALTTO Results Reverberate for Lapatinib, Novel Clinical Trials

June 1st 2014

A dual HER2-blockade strategy that added lapatinib to trastuzumab for the adjuvant treatment of women with early breast cancer failed to demonstrate a significant improvement in DFS over the standard therapy with trastuzumab alone.

Dr. Byrd on Ibrutinib Versus Ofatumumab in CLL

June 1st 2014

John C. Byrd, MD, from The Ohio State University Comprehensive Cancer Center, discusses the promising findings from the phase III RESONATE trial that compared ofatumumab to ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.

Investigational Immunotherapy Granted First Breakthrough Therapy Designation in Bladder Cancer

June 1st 2014

MPDL3280A reduced tumors in 43% of patients with previously treated PD-L1-positive metastatic bladder cancer, resulting in the first breakthrough therapy designation from the FDA for a treatment in this setting.

Ramucirumab Modestly Improves Survival in Advanced NSCLC

June 1st 2014

Adding the VEGFR-2 inhibitor ramucirumab to standard docetaxel improved overall survival by 1.4 months versus docetaxel alone in patients with advanced non–small cell lung cancer.

Dr. Pegram on a Phase II Trial of MGAH22 in Breast Cancer

June 1st 2014

Mark D. Pegram, MD, from the Stanford University Medical Center, discusses a phase II study of margetuximab in patients with relapsed or refractory advanced breast cancer whose tumors express HER2 at the 2+ level by immunohistochemistry and lack evidence of HER2 gene amplification by FISH.

Targeted Therapy Combination Improves PFS in Ovarian Cancer

May 31st 2014

Combining the oral targeted agents olaparib and cediranib resulted in a near-doubling of median progression-free survival (PFS) among women with recurrent ovarian cancer in a phase II study highlighted Saturday during the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.

Ibrutinib Triples PFS, Doubles OS in Phase III CLL Trial

May 31st 2014

Treatment with single-agent ibrutinib dramatically increased PFS by nearly 80% and significantly extended OS by 57% compared with ofatumumab in patients with relapsed or refractory CLL.

Lenvatinib Likely to Become Standard in Resistant Differentiated Thyroid Cancer

May 31st 2014

Lenvatinib, a novel multityrosine kinase inhibitor, is highly effective against differentiated thyroid cancer that has become resistant to standard RAI therapy.

NEXT PAGE
PREVIOUS PAGE
x